ERYDERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERYDERM (ERYDERM).
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation.
| Metabolism | Erythromycin is metabolized primarily in the liver via demethylation by CYP3A4. |
| Excretion | Erythromycin is primarily excreted via the biliary route (~80%) as unchanged drug and metabolites, with renal excretion accounting for ~10-15%. Fecal elimination is minimal (~2-4%). |
| Half-life | Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function, but can extend to 4-6 hours in patients with severe hepatic impairment. |
| Protein binding | Erythromycin is approximately 70-90% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into extracellular and intracellular fluid, with high tissue penetration. |
| Bioavailability | Oral erythromycin base: 35-45% (enteric-coated); estolate: 25-40%; ethylsuccinate: 70-80% (food decreases absorption). Intravenous: 100%. Topical: minimal systemic absorption (<1%). |
| Onset of Action | Oral: 1-2 hours; Intravenous: 30 minutes; Topical: 2-3 days for clinical improvement in acne. |
| Duration of Action | Oral/IV: 6-8 hours; Topical: continuous with regular application; clinical effect in acne may require 4-8 weeks. |
| Molecular Weight | 733.93 |
Topical: Apply a thin film to affected area twice daily for 2-4 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for topical use due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for topical use. |
| Pediatric use | Children ≥2 years: Apply topically twice daily for 2 weeks; children <2 years: not recommended. |
| Geriatric use | No specific dose adjustment needed; use same as adult dosing. |
| 1st trimester | Erythromycin (active ingredient in ERYDERM) is generally considered safe in the first trimester, but topical use is preferred due to minimal systemic absorption. Avoid if eardrum perforation (ototoxic potential). |
| 2nd trimester | No evidence of teratogenicity from topical erythromycin in second trimester. Use with caution if eardrum perforation. |
| 3rd trimester | Topical erythromycin safe in third trimester; no risk of premature closure of ductus arteriosus or neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for ERYDERM (ERYDERM).
| Placental transfer | Minimal systemic absorption from topical application; no evidence of significant placental transfer. Oral erythromycin crosses the placenta, but topical use results in negligible maternal plasma levels. |
| Breastfeeding | Topical erythromycin is unlikely to achieve significant systemic levels; therefore, it is considered safe during breastfeeding. Avoid application to breast or nipple area to prevent infant ingestion. Oral erythromycin is compatible with breastfeeding, but topical use is preferred. |
■ FDA Black Box Warning
No FDA black box warning for topical erythromycin.
| Serious Effects |
Hypersensitivity to erythromycin or any component of ERYDERMPreexisting hearing loss (if applied to eardrum perforation)
| Precautions | May cause irritation, sensitization, or superinfection; prolonged use may result in fungal overgrowth. |
| Food/Dietary | No clinically significant food interactions. Avoid ingestion; for external use only. |
| Clinical Pearls | EryDerm (erythromycin topical) is a macrolide antibiotic effective against Propionibacterium acnes. It is often used in acne vulgaris. Application to inflamed lesions may cause transient stinging. Combination with benzoyl peroxide reduces antibiotic resistance risk. Avoid contact with eyes, mouth, and mucous membranes. Use with caution in patients with hepatic impairment due to potential systemic absorption. |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Erythromycin (topical) has no known teratogenic effects; systemic absorption minimal. No fetal risk documented in any trimester. |
| Fetal Monitoring | No specific monitoring required due to negligible systemic exposure. |
| Fertility Effects | No known effects on fertility. |
| Patient Advice | Apply a thin layer to affected areas once or twice daily as directed. · Wash hands before and after application. · Avoid contact with eyes, mouth, and cut or broken skin. · Mild burning or stinging may occur upon application; if severe, discontinue use. · Do not use with other topical products unless advised by your doctor. · Sun exposure should be minimized; use sunscreen and protective clothing. · If no improvement in 6-8 weeks, consult your healthcare provider. · Inform your doctor if you are pregnant, breastfeeding, or have liver disease. |